SCYX
Price
$0.84
Change
+$0.04 (+5.00%)
Updated
Aug 15 closing price
Capitalization
32.77M
81 days until earnings call
TLRY
Price
$1.03
Change
-$0.15 (-12.71%)
Updated
Aug 15 closing price
Capitalization
1.13B
47 days until earnings call
Interact to see
Advertisement

SCYX vs TLRY

Header iconSCYX vs TLRY Comparison
Open Charts SCYX vs TLRYBanner chart's image
SCYNEXIS
Price$0.84
Change+$0.04 (+5.00%)
Volume$106.24K
Capitalization32.77M
Tilray Brands
Price$1.03
Change-$0.15 (-12.71%)
Volume$90.05M
Capitalization1.13B
SCYX vs TLRY Comparison Chart in %
Loading...
SCYX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SCYX vs. TLRY commentary
Aug 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SCYX is a Hold and TLRY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 17, 2025
Stock price -- (SCYX: $0.84 vs. TLRY: $1.03)
Brand notoriety: SCYX: Not notable vs. TLRY: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: SCYX: 57% vs. TLRY: 170%
Market capitalization -- SCYX: $32.77M vs. TLRY: $1.13B
SCYX [@Pharmaceuticals: Generic] is valued at $32.77M. TLRY’s [@Pharmaceuticals: Generic] market capitalization is $1.13B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.75B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SCYX’s FA Score shows that 0 FA rating(s) are green whileTLRY’s FA Score has 0 green FA rating(s).

  • SCYX’s FA Score: 0 green, 5 red.
  • TLRY’s FA Score: 0 green, 5 red.
According to our system of comparison, both SCYX and TLRY are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SCYX’s TA Score shows that 6 TA indicator(s) are bullish while TLRY’s TA Score has 4 bullish TA indicator(s).

  • SCYX’s TA Score: 6 bullish, 4 bearish.
  • TLRY’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SCYX is a better buy in the short-term than TLRY.

Price Growth

SCYX (@Pharmaceuticals: Generic) experienced а -2.90% price change this week, while TLRY (@Pharmaceuticals: Generic) price change was +58.78% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +4.25%. For the same industry, the average monthly price growth was +10.98%, and the average quarterly price growth was +78.05%.

Reported Earning Dates

SCYX is expected to report earnings on Nov 05, 2025.

TLRY is expected to report earnings on Oct 02, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+4.25% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TLRY($1.13B) has a higher market cap than SCYX($32.8M). TLRY YTD gains are higher at: -22.556 vs. SCYX (-30.587). SCYX has higher annual earnings (EBITDA): -26.67M vs. TLRY (-2.13B). TLRY has more cash in the bank: 256M vs. SCYX (40.6M). SCYX has less debt than TLRY: SCYX (2.49M) vs TLRY (329M). TLRY has higher revenues than SCYX: TLRY (821M) vs SCYX (2.63M).
SCYXTLRYSCYX / TLRY
Capitalization32.8M1.13B3%
EBITDA-26.67M-2.13B1%
Gain YTD-30.587-22.556136%
P/E Ratio0.91N/A-
Revenue2.63M821M0%
Total Cash40.6M256M16%
Total Debt2.49M329M1%
FUNDAMENTALS RATINGS
SCYX vs TLRY: Fundamental Ratings
SCYX
TLRY
OUTLOOK RATING
1..100
721
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
53
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
6335
P/E GROWTH RATING
1..100
9894
SEASONALITY SCORE
1..100
1550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SCYX's Valuation (45) in the Pharmaceuticals Other industry is in the same range as TLRY (53) in the Biotechnology industry. This means that SCYX’s stock grew similarly to TLRY’s over the last 12 months.

SCYX's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as TLRY (100) in the Biotechnology industry. This means that SCYX’s stock grew similarly to TLRY’s over the last 12 months.

SCYX's SMR Rating (96) in the Pharmaceuticals Other industry is in the same range as TLRY (98) in the Biotechnology industry. This means that SCYX’s stock grew similarly to TLRY’s over the last 12 months.

TLRY's Price Growth Rating (35) in the Biotechnology industry is in the same range as SCYX (63) in the Pharmaceuticals Other industry. This means that TLRY’s stock grew similarly to SCYX’s over the last 12 months.

TLRY's P/E Growth Rating (94) in the Biotechnology industry is in the same range as SCYX (98) in the Pharmaceuticals Other industry. This means that TLRY’s stock grew similarly to SCYX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SCYXTLRY
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 11 days ago
81%
Bullish Trend 4 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
SCYX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MFRHX62.17N/A
N/A
MFS Research R3
EMFIX12.83N/A
N/A
Ashmore Emerging Markets Equity Instl
SNWAX63.87N/A
N/A
Easterly Snow Small Cap Value A
OCLVX19.77-0.08
-0.40%
Optimum Large Cap Value C
EQNRX23.03-0.10
-0.43%
MFS Equity Income R1

SCYX and

Correlation & Price change

A.I.dvisor tells us that SCYX and AKAN have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SCYX and AKAN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCYX
1D Price
Change %
SCYX100%
+4.78%
AKAN - SCYX
32%
Poorly correlated
N/A
ELAN - SCYX
30%
Poorly correlated
-0.22%
AQST - SCYX
29%
Poorly correlated
N/A
CRDL - SCYX
28%
Poorly correlated
-2.24%
TLRY - SCYX
28%
Poorly correlated
-12.71%
More

TLRY and

Correlation & Price change

A.I.dvisor indicates that over the last year, TLRY has been closely correlated with SNDL. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if TLRY jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TLRY
1D Price
Change %
TLRY100%
-12.71%
SNDL - TLRY
76%
Closely correlated
-4.27%
CGC - TLRY
61%
Loosely correlated
-12.75%
CRON - TLRY
60%
Loosely correlated
-5.95%
OGI - TLRY
59%
Loosely correlated
-8.33%
ACB - TLRY
55%
Loosely correlated
-5.75%
More